Stockpolly
Search
CBIO · NASDAQ · Biotechnology

Crescent Biopharma (CBIO)

Develops antibody medicines for solid tumors through bispecific and ADC programs.

$18.27
Pre-market−0.24 (−1.30%)
At close$18.51(+3.23%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue0000000001110
Gross profit0000000001110
1010111011171421261022626
Research & development5566214111220951819
545443496789
General & administrative545443496789
Other expenses00006000000−2
Operating income−10−10−11−10−11−17−14−21−26−91−25−26
11001−1−1−11112
Interest income110000001112
Interest expense000001110000
Other non-operating income0000−6000−1−1−1−2
Income before tax−9−9−11−10−10−18−15−22−25−90−23−25
Income tax expense000000000200
Net income from continuing operations−9−9−11−10−10−18−15−22−25−92−23−25
Other adjustments000000000000
Net income−9−9−11−10−10−18−15−22−25−92−23−23
EPS, basic−$0.14−$14.10−$16.66−$15.66−$15.24−$27.71−$19.63−$5.65−$1.49−$4.58−$0.77−$0.74
EPS, diluted−$0.14−$14.10−$16.66−$15.66−$15.24−$27.71−$19.63−$5.65−$1.49−$4.58−$0.77−$0.74
Weighted average shares, basic64111111417203031
Weighted average shares, diluted64111111417203031
EBITDA−10−10−11−10−618−14−21−25−90−23−25
Depreciation & amortization0000035000000
EBIT−10−10−11−10−6−17−14−21−25−90−23−25